At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RYTM Rhythm Pharmaceuticals Inc.
Post-Market Trading 12-23 18:33:13 EST
56.04
-0.08
-0.14%
盘后56.04
+0.000.00%
16:20 EST
High56.60Low54.29Vol904.98K
Open55.24D1 Closing56.12Amplitude4.12%
Mkt Cap3.44BTradable Cap2.52BTotal Shares61.46M
T/O50.23MT/O Rate2.01%Tradable Shares45.06M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years
Simply Wall St.  ·  12-23 21:27
Rhythm Pharmaceuticals' (NASDAQ:RYTM) investors will be pleased with their incredible 370% return over the last three years
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-23 20:00
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children
Dow Jones  ·  12-21
FDA Expands Rhythm Pharma Obesity Drug Approval to Younger Children
Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use
MT Newswires Live  ·  12-21
Rhythm Pharmaceuticals Gains FDA Approval for Expanded IMCIVREE Use
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Benzinga  ·  12-21
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential
Rhythm announces FDA approval of Imcivree for patients as young as 2
TIPRANKS  ·  12-21
Rhythm announces FDA approval of Imcivree for patients as young as 2
BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old
Reuters  ·  12-21
BRIEF-Rhythm Pharmaceuticals Announces FDA Approval Of Imcivree(Setmelanotide) For Patients As Young As 2 Years Old
Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old
THOMSON REUTERS  ·  12-21
Rhythm Pharmaceuticals Announces FDA Approval of Imcivree® (Setmelanotide) for Patients as Young as 2 Years Old
Top Calls on Wall Street: FedEx, Nike, Affirm, BlackBerry, Merck, Oracle, Reddit, and More
The Fly  ·  12-20
Top Calls on Wall Street: FedEx, Nike, Affirm, BlackBerry, Merck, Oracle, Reddit, and More
Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target
MT Newswires Live  ·  12-20
Oppenheimer Initiates Coverage on Rhythm Pharmaceuticals With Outperform Rating, $76 Price Target
Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Dow Jones  ·  12-06
Rhythm Pharmaceuticals Is Maintained at Buy by Goldman Sachs
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
Dow Jones  ·  12-04
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
Nvidia Chipmaker Taiwan Semi Hits Buy Point Following Bullish Advance
Blockhead  ·  12-03
Nvidia Chipmaker Taiwan Semi Hits Buy Point Following Bullish Advance
Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK
MT Newswires Live  ·  12-03
Rhythm Pharmaceuticals Says Imcivree Receives Expanded Marketing Authorization in UK
Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree
TIPRANKS  ·  12-03
Rhythm Pharmaceuticals: MHRA expands marketing authorization for Imcivree
Rhythm Pharmaceuticals Inc - Imcivree Expected to Be Available by Year-End Through Medicines for Children Program
THOMSON REUTERS  ·  12-03
Rhythm Pharmaceuticals Inc - Imcivree Expected to Be Available by Year-End Through Medicines for Children Program
Rhythm Pharmaceuticals Announces ▼ Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency to Include Children as Young as 2 Years Old
THOMSON REUTERS  ·  12-03
Rhythm Pharmaceuticals Announces ▼ Imcivree® (Setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients With Bardet Biedl Syndrome or Pomc, Pcsk1, or Lepr Deficiency to Include Children as Young as 2 Years Old
Fintech Approaches Buy Point Of Extremely Rare Pattern Following 44% Burst
Blockhead  ·  11-27
Fintech Approaches Buy Point Of Extremely Rare Pattern Following 44% Burst
Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge
Blockhead  ·  11-26
Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.
Dow Jones  ·  11-25
Rhythm Pharmaceuticals Price Target Maintained With a $69.00/Share by HC Wainwright & Co.

Introduction

Company Name.
Rhythm Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Issue price:
--